<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6803859</article-id><article-id pub-id-type="doi">10.3390/molecules24193562</article-id><article-id pub-id-type="publisher-id">molecules-24-03562</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Structural Basis for the Regulation of PPAR&#x003b3; Activity by Imatinib</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Jun Young</given-names></name><xref ref-type="aff" rid="af1-molecules-24-03562">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyun-Jung</given-names></name><xref ref-type="aff" rid="af2-molecules-24-03562">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7571-3791</contrib-id><name><surname>Han</surname><given-names>Byung Woo</given-names></name><xref ref-type="aff" rid="af1-molecules-24-03562">1</xref><xref rid="c1-molecules-24-03562" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-molecules-24-03562"><label>1</label>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Korea; <email>nosvc4@snu.ac.kr</email></aff><aff id="af2-molecules-24-03562"><label>2</label>College of Pharmacy, Chung-Ang University, Seoul 06974, Korea; <email>hyunjungkim@cau.ac.kr</email></aff><author-notes><corresp id="c1-molecules-24-03562"><label>*</label>Correspondence: <email>bwhan@snu.ac.kr</email>; Tel.: +82-2-880-7898</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>24</volume><issue>19</issue><elocation-id>3562</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;) phosphorylation at Ser245 to evaluate possibilities of antidiabetic drug repositioning, imatinib was determined as a PPAR&#x003b3; antagonist ligand. However, it is not well understood how imatinib binds to PPAR&#x003b3; or would improve insulin sensitivity without classical agonism. Here, we report the crystal structure of the PPAR&#x003b3; R288A mutant in complex with imatinib. Imatinib bound to Arm2 and Arm3 regions in the ligand-binding domain (LBD) of PPAR&#x003b3;, of which the Arm3 region is closely related to the inhibition of PPAR&#x003b3; phosphorylation at Ser245. The binding of imatinib in LBD induced a stable conformation of helix H2&#x02032; and the &#x003a9; loop compared with the ligand-free state. In contrast, imatinib does not interact with Tyr473 on PPAR&#x003b3; helix H12, which is important for the classical agonism associated with side effects. Our study provides new structural insights into the PPAR&#x003b3; regulation by imatinib and may contribute to the development of new antidiabetic drugs targeting PPAR&#x003b3; while minimizing known side effects.</p></abstract><kwd-group><kwd>imatinib</kwd><kwd>PPAR&#x003b3;</kwd><kwd>antidiabetic drug</kwd><kwd>type 2 diabetes</kwd><kwd>crystal structure</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-24-03562"><title>1. Introduction</title><p>Peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;) belongs to the thyroid hormone receptor-like nuclear receptor subfamily 1, which is one of the ligand-activated transcription factors [<xref rid="B1-molecules-24-03562" ref-type="bibr">1</xref>]. PPAR&#x003b3; forms a heterodimer with retinoid X receptors (RXRs), recruits coactivators, and then binds to the cognate peroxisome proliferative response elements on target genes [<xref rid="B2-molecules-24-03562" ref-type="bibr">2</xref>]. Through this process, PPAR&#x003b3; regulates the transcription of target genes, which plays an important role in adipocyte differentiation, lipid metabolism, glucose homeostasis, insulin sensitization, and inflammation [<xref rid="B3-molecules-24-03562" ref-type="bibr">3</xref>,<xref rid="B4-molecules-24-03562" ref-type="bibr">4</xref>]. Thus, PPAR&#x003b3; is a good therapeutic target for type 2 diabetes mellitus, as well as other metabolic diseases including obesity and atherosclerosis [<xref rid="B5-molecules-24-03562" ref-type="bibr">5</xref>].</p><p>Compared with other nuclear receptors, PPAR&#x003b3; contains a considerably larger Y-shaped ligand-binding pocket (LBP) with a volume of 1300&#x02013;1440 &#x000c5;<sup>3</sup> and is known to be activated by numerous endogenous and synthetic ligands [<xref rid="B6-molecules-24-03562" ref-type="bibr">6</xref>,<xref rid="B7-molecules-24-03562" ref-type="bibr">7</xref>,<xref rid="B8-molecules-24-03562" ref-type="bibr">8</xref>]. Types of synthetic PPAR&#x003b3; ligands are typically represented as full agonists, partial agonists, and antagonists. PPAR&#x003b3; full agonists induce a conformational change of helix H12 via hydrogen bond networks with Tyr473 of helix H12, His323 of helix H5, and His449 of helix H10 to recruit coactivators, thereby resulting in strong adipogenesis-related transcriptional agonism [<xref rid="B6-molecules-24-03562" ref-type="bibr">6</xref>,<xref rid="B9-molecules-24-03562" ref-type="bibr">9</xref>]. As PPAR&#x003b3; full agonists, thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, have been widely used in treating type 2 diabetes mellitus due to their potent insulin-sensitizing effects [<xref rid="B8-molecules-24-03562" ref-type="bibr">8</xref>]. However, TZDs have been prescribed with caution due to their known side effects, including weight gain, fluid retention, increased adipogenesis, and bone loss [<xref rid="B9-molecules-24-03562" ref-type="bibr">9</xref>,<xref rid="B10-molecules-24-03562" ref-type="bibr">10</xref>]. Compared with PPAR&#x003b3; full agonist, PPAR&#x003b3; partial agonists bind differently to the ligand-binding domain (LBD) of PPAR&#x003b3;, which preferentially stabilize the four-stranded &#x003b2;-sheet and helix H3, but leave helix H12 in a very dynamic state [<xref rid="B11-molecules-24-03562" ref-type="bibr">11</xref>,<xref rid="B12-molecules-24-03562" ref-type="bibr">12</xref>]. PPAR&#x003b3; partial agonists have diminished agonist efficacy compared with full agonists, but may retain excellent insulin-sensitizing effects without causing side effects as much as full agonists [<xref rid="B11-molecules-24-03562" ref-type="bibr">11</xref>,<xref rid="B12-molecules-24-03562" ref-type="bibr">12</xref>]. In addition, PPAR&#x003b3; partial agonists may induce a differential recruitment of beneficial coactivators associated with regulating glucose metabolism, energy expenditure, and adipocyte differentiation [<xref rid="B13-molecules-24-03562" ref-type="bibr">13</xref>]. Thus, PPAR&#x003b3; partial agonists are another class of compounds that activate PPAR&#x003b3; with sufficient insulin-sensitizing efficacy, accompanied by few side effects.</p><p>A major challenge in developing safer antidiabetic compounds targeting PPAR&#x003b3; is to maintain the advantageous insulin-sensitizing effects of PPAR&#x003b3; ligands while minimizing these undesirable side effects. In 2010, the phosphorylation of PPAR&#x003b3; at Ser245 (in PPAR&#x003b3;1; Ser273 in PPAR&#x003b3;2) by cyclin-dependent kinase 5 (Cdk5) was shown to be linked to insulin resistance [<xref rid="B14-molecules-24-03562" ref-type="bibr">14</xref>]. Cdk5-mediated phosphorylation of PPAR&#x003b3; does not affect its classical transcriptional activity; however, it can lead to impairment in the regulation of genes involved in insulin sensitivity such as adiponectin and adipsin [<xref rid="B14-molecules-24-03562" ref-type="bibr">14</xref>]. Various synthetic PPAR&#x003b3; ligands such as full agonists, partial agonists, and antagonists have been shown to induce graded PPAR&#x003b3; transcriptional agonism, yet they effectively block the phosphorylation of PPAR&#x003b3; at Ser245 to similar degrees [<xref rid="B11-molecules-24-03562" ref-type="bibr">11</xref>,<xref rid="B14-molecules-24-03562" ref-type="bibr">14</xref>]. Recently, structural studies revealed that the alternate binding site and the hydrophobic region between helix H3 and the four-stranded &#x003b2;-sheet of PPAR&#x003b3; could affect PPAR&#x003b3; phosphorylation at Ser245 [<xref rid="B15-molecules-24-03562" ref-type="bibr">15</xref>,<xref rid="B16-molecules-24-03562" ref-type="bibr">16</xref>]. Thus, other ligands selectively targeting these regions would be potential candidates as a potent antidiabetic drug with reduced side effects.</p><p>Imatinib is a well-known anticancer drug to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive, some gastrointestinal stromal tumors, and other cancer-related syndromes [<xref rid="B17-molecules-24-03562" ref-type="bibr">17</xref>,<xref rid="B18-molecules-24-03562" ref-type="bibr">18</xref>,<xref rid="B19-molecules-24-03562" ref-type="bibr">19</xref>]. Imatinib is the first-generation drug of a BCR-ABL tyrosine kinase inhibitor (<xref ref-type="fig" rid="molecules-24-03562-f001">Figure 1</xref>) [<xref rid="B20-molecules-24-03562" ref-type="bibr">20</xref>]. Interestingly, imatinib was recently identified as a PPAR&#x003b3; antagonist ligand that improves insulin sensitivity without classical agonism from a drug repositioning screening of an FDA-approved drug library [<xref rid="B21-molecules-24-03562" ref-type="bibr">21</xref>]. Imatinib directly bound to PPAR&#x003b3; and inhibited the Cdk5-mediated phosphorylation of PPAR&#x003b3; in a dose-dependent manner [<xref rid="B21-molecules-24-03562" ref-type="bibr">21</xref>]. However, its exact binding mode as a PPAR&#x003b3; phosphorylation site inhibitor has not been revealed. Here, we report the crystal structure of PPAR&#x003b3; R288A mutant in complex with imatinib.</p></sec><sec sec-type="results" id="sec2-molecules-24-03562"><title>2. Results</title><sec id="sec2dot1-molecules-24-03562"><title>2.1. Overall Structure of Imatinib-Bound PPAR&#x003b3; R288A Mutant LBD</title><p>Imatinib is a 2-phenylaminopyrimidine derivative that is chemically distinct from the thiazolidinedione (TZD) class of PPAR&#x003b3; full agonists (<xref ref-type="fig" rid="molecules-24-03562-f001">Figure 1</xref>). To gain insights into the binding mode of PPAR&#x003b3; phosphorylation site inhibitor imatinib, we determined the crystal structure of the PPAR&#x003b3; R288A mutant LBD in complex with imatinib in the presence of a peptide derived from human steroid receptor coactivator-1 (SRC-1) at 2.75 &#x000c5; resolution. We were unable to resolve the crystal structure of imatinib-bound PPAR&#x003b3; wild-type (WT) LBD. However, from previously reported PPAR&#x003b3; LBD structures, we found that Arg288 was very flexible depending on ligands. More interestingly, PPAR&#x003b3; R288H mutation was observed in colon cancer patients and inhibited the binding of endogenous ligands [<xref rid="B22-molecules-24-03562" ref-type="bibr">22</xref>]. To reduce the effect of Arg288 on ligand binding, we generated the PPAR&#x003b3; R288A mutant LBD construct and could resolve the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure. Crystals of imatinib-bound PPAR&#x003b3; R288A mutant LBD belonged to the <italic>orthorhombic</italic> space group <italic>P</italic>2<sub>1</sub>2<sub>1</sub>2 and contained one monomer in an asymmetric unit. The overall structure resembled LBDs of the other nuclear receptors with 13 &#x003b1;-helices and a mixed four-stranded &#x003b2;-sheet (<xref ref-type="fig" rid="molecules-24-03562-f002">Figure 2</xref>A). The Cdk5-mediated phosphorylation site Ser245 of PPAR&#x003b3; LBD was located on the loop between helix H2 and strand &#x003b2;1. The C-terminal helix H12 was folded over the LBP in an active conformation. Helices H3, H4, and H12 surrounded a shallow hydrophobic groove, which was the binding site for the helical LxxLL motif of the SRC-1 coactivator.</p></sec><sec id="sec2dot2-molecules-24-03562"><title>2.2. Imatinib Occupies Arm2 and Arm3 Regions in PPAR&#x003b3; R288A Mutant LBD</title><p>In the structure of imatinib-bound PPAR&#x003b3; R288A mutant LBD, we observed a clear extra electron density calculated from the final refined model. The omit map could be modeled explicitly with imatinib (<xref ref-type="fig" rid="molecules-24-03562-f002">Figure 2</xref>C). To compare the binding mode of imatinib with other PPAR&#x003b3; ligands, we superimposed 144 structures of PPAR&#x003b3; complexed with many different ligands onto the imatinib-bound PPAR&#x003b3; R288A mutant LBD. Superposition of many other ligands indicated that Arm1, Arm2, and Arm3 regions were formed in the PPAR&#x003b3; LBP, of which imatinib occupied the Arm2 and Arm3 regions (<xref ref-type="fig" rid="molecules-24-03562-f003">Figure 3</xref>). The primary interaction between imatinib and PPAR&#x003b3; R288A mutant LBD was hydrophobic effects (<xref ref-type="fig" rid="molecules-24-03562-f002">Figure 2</xref>B). The benzamide ring and N-methylpiperazine ring of imatinib were in contact with a pocket in the Arm2 region, consisting of residues from the H1&#x02013;H2 loop (Leu228, Thr229, and Lys230) and helix H5 (Ile326, Met329, Leu330, and Leu333). The methylbenzene ring and pyridylpyrimidine moiety of imatinib were surrounded by residues from helix H2&#x02032; (Glu259), &#x003a9; loop (Ile262, Lys263, and Lys265), helix H3 (Gly284, Cys285, and Arg288Ala), strand &#x003b2;3 (Ile341 and Ser342), and helix H7 (Met364) in the Arm3 region. Imatinib did not occupy the Arm1 region and had no interaction with the residue Tyr473 of helix H12, which is commonly presented in the TZD-bound PPAR&#x003b3; (<xref ref-type="fig" rid="molecules-24-03562-f003">Figure 3</xref>). In general, the binding mode of the imatinib molecule in complex with kinase proteins adopted two conformations. First, imatinib bound to the ABL kinase (Protein Data Bank (PDB) ID: 1IEP), adopting a trans-conformation with the methylbenzene and benzamide rings trans to the pyridylpyrimidine moiety (<xref ref-type="app" rid="app1-molecules-24-03562">Figure S1</xref>) [<xref rid="B24-molecules-24-03562" ref-type="bibr">24</xref>]. In the structure of the imatinib-bound Syk kinase (PDB ID: 1XBB), imatinib bound in a cis conformation, with the methylbenzene and benzamide rings cis to the pyridylpyrimidine moiety (<xref ref-type="app" rid="app1-molecules-24-03562">Figure S1</xref>) [<xref rid="B25-molecules-24-03562" ref-type="bibr">25</xref>]. The binding mode of the imatinib molecule in complex with the PPAR&#x003b3; R288A mutant LBD resembled the trans conformation in the imatinib-ABL complex structure (<xref ref-type="fig" rid="molecules-24-03562-f002">Figure 2</xref>).</p></sec><sec id="sec2dot3-molecules-24-03562"><title>2.3. Imatinib Binding Induced Conformational Change of H9-H10 Loop</title><p>To further gain structural insight into imatinib, we also determined the crystal structure of the ligand-free PPAR&#x003b3; R288A mutant LBD in the presence of the SRC-1 peptide. The overall structures of ligand-free PPAR&#x003b3; WT LBD (PDB ID: 6JQ7) and ligand-free PPAR&#x003b3; R288A mutant LBD were not significantly different, with root-mean-square deviation (RMSD) of 0.27 &#x000c5; for 259 C&#x003b1; atoms. When the C&#x003b1; RMSD values were compared for ligand-free PPAR&#x003b3; WT LBD vs. imatinib-bound PPAR&#x003b3; R288A mutant LBD and ligand-free PPAR&#x003b3; R288A mutant LBD vs. imatinib-bound PPAR&#x003b3; R288A mutant LBD, we observed a large conformational change between residues Asn424 and Leu431 located in the H9&#x02013;H10 loop (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>A and <xref ref-type="fig" rid="molecules-24-03562-f005">Figure 5</xref>A). In the ligand-free states of PPAR&#x003b3; WT LBD and PPAR&#x003b3; R288A mutant LBD, the O&#x003b4; atoms of Asp380 formed a hydrogen bonding network with the O&#x003b3; atom of Ser382 and the N&#x003b4; atom of Asn424 with a distance of 2.6 &#x000c5; and 3.0 &#x000c5;, respectively (<xref ref-type="fig" rid="molecules-24-03562-f005">Figure 5</xref>B and <xref ref-type="app" rid="app1-molecules-24-03562">Figure S2</xref>). However, when imatinib bound to PPAR&#x003b3; R288A mutant LBD, the electron densities of residues Asp380 and Asn424 were weakened, and the hydrogen bonding network disappeared (<xref ref-type="fig" rid="molecules-24-03562-f005">Figure 5</xref>C). Thus, the binding of imatinib to PPAR&#x003b3; LBD increased the side chain flexibility of Asp380, resulting in a conformational change of this region.</p></sec><sec id="sec2dot4-molecules-24-03562"><title>2.4. Imatinib Binding in PPAR&#x003b3; LBD Stabilizes Helix H2&#x02032; and &#x003a9; Loop</title><p>To investigate changes in protein dynamics of PPAR&#x003b3; LBD caused by imatinib binding, we compared normalized B-factors of the structures (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>B). The B-factors of the structures were normalized to have a zero mean distribution and unit variance based on the mean value and standard deviation of the distribution of observed B-factors, as previously reported [<xref rid="B26-molecules-24-03562" ref-type="bibr">26</xref>]. We observed that PPAR&#x003b3; LBD was flexible in the H2&#x02013;&#x003b2;1 loop, the region around the &#x003a9; loop, and the H11&#x02013;H12 loop due to the inherent characteristics of PPAR&#x003b3; LBD. The most distinctive structural difference in imatinib binding, as determined by B-factor comparative analysis, was the stability of the helix H2&#x02032; and the &#x003a9; loop regions relative to the ligand-free state. The four-stranded &#x003b2;-sheet region was also slightly stabilized by imatinib binding. As shown in <xref ref-type="fig" rid="molecules-24-03562-f006">Figure 6</xref>, we found that the distance between the C&#x003b4; atom of Ile341 and the C&#x003b4; atom of Leu255 changed from 6.9 &#x000c5; in the ligand-free states to 6.3 &#x000c5; in the imatinib-bound structure (<xref ref-type="app" rid="app1-molecules-24-03562">Figure S3</xref>). These results showed that imatinib binding enhanced the hydrophobic interaction network of Ile249, Leu255, Ile341, and Met348 in the Arm3 region. Moreover, Ile262 of the &#x003a9; loop was also stabilized by imatinib binding and was newly involved in this hydrophobic interaction network (<xref ref-type="fig" rid="molecules-24-03562-f006">Figure 6</xref>B). The &#x003a9; loop of ligand-free PPAR&#x003b3; WT LBD and R288A mutant LBD structures could not be modeled due to missing electron density (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>B and <xref ref-type="fig" rid="molecules-24-03562-f006">Figure 6</xref>A). However, the &#x003a9; loop, up to residue His266, could be observed in the imatinib-bound structure (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>B and <xref ref-type="fig" rid="molecules-24-03562-f006">Figure 6</xref>B).</p></sec><sec id="sec2dot5-molecules-24-03562"><title>2.5. Imatinib has Higher Binding Affinity for PPAR&#x003b3; R288A Mutant LBD than PPAR&#x003b3; WT LBD</title><p>To confirm whether imatinib can interact with PPAR&#x003b3; WT LBD and PPAR&#x003b3; R288A mutant LBD, the binding affinities of imatinib for PPAR&#x003b3; WT LBD and PPAR&#x003b3; R288A mutant LBD were measured by surface plasmon resonance (SPR) analysis. SPR analysis was performed using a Biacore T200 apparatus to measure real-time interactions between imatinib molecules and PPAR&#x003b3; LBD proteins coupled to sensor chips in constant flow. PPAR&#x003b3; WT LBD and PPAR&#x003b3; R288A mutant LBD were immobilized on the CM5 sensor chip in an immobilization level of approximately 7000 response units (RU). For controls, reference cells were deactivated with ethanolamine (no immobilized PPAR&#x003b3; LBD). Imatinib was injected over the chips at concentrations ranging from 0.625 to 10 &#x000b5;M. The sensorgram for the interaction of imatinib with PPAR&#x003b3; R288A mutant LBD is shown in <xref ref-type="fig" rid="molecules-24-03562-f007">Figure 7</xref>A. The SPR response data were then fit to the simple bimolecular 1:1 Langmuir isotherm binding model using Biacore T200 evaluation software 3.0 (GE Healthcare). According to these data, PPAR&#x003b3; R288A mutant LBD showed rapid association and dissociation rates with imatinib molecules and an equilibrium binding constant (<italic>K<sub>d</sub></italic>) of 152 nM (<xref ref-type="fig" rid="molecules-24-03562-f007">Figure 7</xref>A). We also detected the binding response of PPAR&#x003b3; WT LBD for imatinib with an equilibrium binding constant of 231 nM using the same experimental approach (<xref ref-type="fig" rid="molecules-24-03562-f007">Figure 7</xref>B). SPR analysis showed that PPAR&#x003b3; R288A mutant LBD had a stronger binding affinity for imatinib than PPAR&#x003b3; WT LBD. In a comparative experiment, the equilibrium binding constant of PPAR&#x003b3; WT LBD for rosiglitazone was 32 nM, similar to the previously reported binding constant (<xref ref-type="app" rid="app1-molecules-24-03562">Figure S4</xref>) [<xref rid="B27-molecules-24-03562" ref-type="bibr">27</xref>].</p></sec></sec><sec sec-type="discussion" id="sec3-molecules-24-03562"><title>3. Discussion</title><p>TZDs, such as rosiglitazone and pioglitazone, are potent insulin sensitizers for the treatment of type 2 diabetes mellitus [<xref rid="B8-molecules-24-03562" ref-type="bibr">8</xref>]. However, TZD treatment has been shown to exhibit severe side effects, including weight gain, fluid retention, and bone fracture [<xref rid="B9-molecules-24-03562" ref-type="bibr">9</xref>,<xref rid="B10-molecules-24-03562" ref-type="bibr">10</xref>]. While there have been numerous trials to produce a novel therapeutic agent targeting PPAR&#x003b3; that maintains its insulin-sensitizing effects without side effects, recent studies have shown the molecular mechanism underlying the antidiabetic effects of PPAR&#x003b3; agonists [<xref rid="B14-molecules-24-03562" ref-type="bibr">14</xref>,<xref rid="B15-molecules-24-03562" ref-type="bibr">15</xref>,<xref rid="B16-molecules-24-03562" ref-type="bibr">16</xref>,<xref rid="B28-molecules-24-03562" ref-type="bibr">28</xref>,<xref rid="B29-molecules-24-03562" ref-type="bibr">29</xref>]. PPAR&#x003b3; phosphorylation at Ser245 by Cdk5 does not change classical PPAR&#x003b3; transcriptional agonism; conversely, it dysregulates the expression of insulin-sensitizing adipokines such as adipsin and adiponectin [<xref rid="B14-molecules-24-03562" ref-type="bibr">14</xref>]. Thus, discovering compounds that block PPAR&#x003b3; phosphorylation at Ser245 and lack classical agonism with high binding affinity to PPAR&#x003b3; could be a very good strategy for the development of antidiabetic agents. Recently, Choi et al. identified that imatinib, a well-known anticancer drug, selectively blocked CDK5-mediated PPAR&#x003b3; phosphorylation via a drug-repositioning screening [<xref rid="B21-molecules-24-03562" ref-type="bibr">21</xref>]. Drug repositioning is an attractive approach for the application of existing drugs to new therapeutic opportunities that can minimize the costs and risks of new drug development due to the ready availability of safety, pharmacological activity, and toxicity profiles [<xref rid="B30-molecules-24-03562" ref-type="bibr">30</xref>]. Although the antidiabetic effect of imatinib with PPAR&#x003b3; has been identified, its structural basis remains unknown. Thus, we determined the structure of imatinib-bound PPAR&#x003b3; to more fully understand the interaction of imatinib with PPAR&#x003b3; and confirm the exact binding mode of imatinib in PPAR&#x003b3;.</p><p>In the imatinib-bound structure, the methylbenzene ring and pyridylpyrimidine moiety of imatinib occupy the Arm3 region in PPAR&#x003b3; LBD, which is surrounded by helix H2&#x02032;, the &#x003a9; loop, and the four-stranded &#x003b2;-sheet (<xref ref-type="fig" rid="molecules-24-03562-f003">Figure 3</xref>). Recently, Filho et al. suggested an indirect mechanism of conformational change of the Ile341 side chain by ligand binding to form a hydrophobic interaction network and stabilize the helix H2&#x02032;, blocking the interaction between Cdk5 and PPAR&#x003b3; and causing the impairment of Cdk5-mediated phosphorylation [<xref rid="B31-molecules-24-03562" ref-type="bibr">31</xref>]. Additionally, we found that imatinib binding strengthened the hydrophobic interaction network comprised of Ile249, Leu255, Ile262, Ile341, and Met348 in the Arm3 region and stabilized the surrounding helix H2&#x02032;, the &#x003a9; loop, and the four-stranded &#x003b2;-sheet (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>B and <xref ref-type="fig" rid="molecules-24-03562-f006">Figure 6</xref>). In our previous study, we also reported that the <italic>p</italic>-methoxyphenol group of lobeglitazone stabilized the hydrophobic pocket near the alternate binding site, which is formed by Ile249, Leu255, Ile281, Ile341, and Met348 [<xref rid="B8-molecules-24-03562" ref-type="bibr">8</xref>]. Moreover, other studies have shown that selective PPAR&#x003b3; modulators such as 2-BABAs and amorfrutins, which have an antidiabetic effect, can bind to this hydrophobic pocket [<xref rid="B32-molecules-24-03562" ref-type="bibr">32</xref>,<xref rid="B33-molecules-24-03562" ref-type="bibr">33</xref>]. Based on these results, it would appear that enhancement of the hydrophobic interaction network in the hydrophobic pocket of the Arm3 region, which consists of Ile249, Leu255, Ile262, Ile341, and Met348, by ligand binding affects inhibition of Cdk5-mediated phosphorylation of PPAR&#x003b3;. Therefore, it is believed that imatinib binding to PPAR&#x003b3; has an antidiabetic effect through this mechanism.</p><p>Interestingly, imatinib blocked the Cdk5-mediated phosphorylation of PPAR&#x003b3; but did not induce transcriptional activity of PPAR&#x003b3;, which is related to the side effects of PPAR&#x003b3; agonists [<xref rid="B21-molecules-24-03562" ref-type="bibr">21</xref>]. Further, imatinib binding did not alter the conformational dynamics of helix H12 in hydrogen/deuterium exchange mass spectrometry (HDX-MS) experiments, suggesting that imatinib has no interaction with helix H12, which is associated with classical agonism [<xref rid="B21-molecules-24-03562" ref-type="bibr">21</xref>]. Consistent with HDX-MS data, our structural analysis showed that imatinib did not occupy the Arm1 region and had no interaction with the residue Tyr473 of helix H12, which is important for transcriptional activity of PPAR&#x003b3; (<xref ref-type="fig" rid="molecules-24-03562-f003">Figure 3</xref>). In addition, imatinib deeply bound to the Arm2 region of PPAR&#x003b3;, causing a large structural change between residues Asn424 and Gln430 in the H9&#x02013;H10 loop, which was probably first discovered through our structural data (<xref ref-type="fig" rid="molecules-24-03562-f005">Figure 5</xref>). This structural change of PPAR&#x003b3; is thought to affect binding with the heterodimer partner RXR&#x003b1; and reduce transcriptional activity of PPAR&#x003b3;. Indeed, the crystal structure of PPAR&#x003b3;&#x02013;RXR&#x003b1; DNA complex showed that Ser429 and Gln430 in the H9&#x02013;H10 loop of PPAR&#x003b3; were involved in the interaction between PPAR&#x003b3; LBD and RXR&#x003b1; LBD [<xref rid="B34-molecules-24-03562" ref-type="bibr">34</xref>]. Taken together, these two reasons may be the cause of the lack of classical transcriptional activity of PPAR&#x003b3; by imatinib action.</p><p>Nevertheless, our imatinib binding mode has a limitation because we were only able to obtain the crystal structure using PPAR&#x003b3; R288A mutant LBD, not WT LBD. The overall structures of WT LBD (PDB ID: 6JQ7) and R288A mutant LBD in the ligand-free state were almost identical with the C&#x003b1; RMSD of 0.27 &#x000c5; (<xref ref-type="fig" rid="molecules-24-03562-f004">Figure 4</xref>A) [<xref rid="B35-molecules-24-03562" ref-type="bibr">35</xref>]. In this respect, it is predicted that the binding mode of imatinib in PPAR&#x003b3; WT LBD may not show much difference from the imatinib binding mode in PPAR&#x003b3; R288A mutant LBD of this study. Moreover, we confirmed that imatinib had a similar level of strong binding affinity for PPAR&#x003b3; WT LBD (<italic>K<sub>d</sub></italic> = 231 nM) and PPAR&#x003b3; R288A mutant LBD (<italic>K<sub>d</sub></italic> = 153 nM) through the SPR binding assays (<xref ref-type="fig" rid="molecules-24-03562-f007">Figure 7</xref>). Interestingly, imatinib exhibited slightly better binding affinity in PPAR&#x003b3; R288A mutant LBD than in WT LBD, which seemed to weaken imatinib binding due to the repulsive force resulting from the close proximity between the imatinib molecule and the side chain of Arg288 (<xref ref-type="app" rid="app1-molecules-24-03562">Figure S5</xref>). These additional experiments may suggest that our imatinib binding mode is nearly identical to that of PPAR&#x003b3; WT LBD.</p><p>In conclusion, we have shown that imatinib binding strengthens the hydrophobic interaction network and stabilizes the surrounding helix H2&#x02032;, the &#x003a9; loop, and the four-stranded &#x003b2;-sheet. This confirms the mechanism of ligand binding in the hydrophobic pocket of the Arm3 region affects the inhibition of Cdk5-mediated phosphorylation of PPAR&#x003b3;. In addition, our study provides a structural explanation as to why imatinib binding does not induce classical transcriptional activity of PPAR&#x003b3;. We expect our structural study to shed light on the development of a new generation of PPAR&#x003b3; ligands as antidiabetic drugs.</p></sec><sec id="sec4-molecules-24-03562"><title>4. Materials and Methods</title><sec id="sec4dot1-molecules-24-03562"><title>4.1. Cloning, Expression, and Mutagenesis</title><p>The cloning, expression, purification, and crystallization of human PPAR&#x003b3; LBD were mainly performed as previously reported [<xref rid="B29-molecules-24-03562" ref-type="bibr">29</xref>]. In brief, the construct of human PPAR&#x003b3; WT LBD (residues 195&#x02013;477 in PPAR&#x003b3;1 numbering) was amplified from a human cDNA clone encoding PPAR&#x003b3; (clone ID: hMU000317) by PCR, which was provided from the Korea Human Gene Bank, Medical Genomics Research Center, KRIBB and cloned into the expression vector pET-28b(+) (Novagen, Darmstadt, Germany) with a 21-residue N-terminal fusion tag (MGSSHHHHHH SSGLVPRGSHM). The resulting recombinant PPAR&#x003b3; WT LBD protein contained a thrombin cleavage site in front of the starting residue Ala195, which was overexpressed in <italic>Escherichia coli</italic> Rosetta 2(DE3) strain. A mutation of human PPAR&#x003b3; WT LBD at Arg288 (R288A) was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA) and the mutation was confirmed by DNA sequencing.</p></sec><sec id="sec4dot2-molecules-24-03562"><title>4.2. Purification</title><p>The recombinant PPAR&#x003b3; WT LBD cells were cultured in the Luria&#x02013;Bertani medium containing 30 &#x003bc;g/mL kanamycin at 37 &#x000b0;C until the mid-log phase. After the addition of 0.5 mM isopropyl &#x003b2;-<sc>d</sc>-thiogalactopyranoside, the cells were further cultured for 20 h at 18 &#x000b0;C. The cells were harvested by centrifugation and lysed by sonication in buffer A (20 mM Tris-HCl at pH 8.5, 150 mM NaCl, 10% (<italic>v</italic>/<italic>v</italic>) glycerol and 0.1 mM tris(2-carboxyethyl) phosphine hydrochloride) containing 5 mM imidazole and 1 mM phenylmethylsulfonyl fluoride. The suspension was centrifuged for 1 h, and the supernatant was filtered using a 0.22 &#x003bc;m syringe filter. The filtrate was applied onto a HiTrap Chelating HP column (GE Healthcare, Chicago, IL, USA), which was pre-equilibrated with buffer A containing 5 mM imidazole. Upon applying a linear gradient of imidazole in the same buffer, PPAR&#x003b3; WT LBD was eluted at 50&#x02013;100 mM imidazole concentration. The eluent was desalted in buffer A using a HiPrep 26/10 column (GE Healthcare, Chicago, IL, USA) before cleaving the purified protein with 2 units of thrombin (Merck Millipore, Darmstadt, Germany) per mg of PPAR&#x003b3; LBD. After cleavage with thrombin, both the N-terminal fusion tag and the uncleaved protein were removed on a HiTrap Chelating HP column (GE Healthcare, Chicago, IL, USA). The flow-through was applied to a HiLoad XK-16 Superdex 200 prep-grade column (GE Healthcare, Chicago, IL, USA), which was pre-equilibrated with buffer A. The purified PPAR&#x003b3; WT LBD was pooled and concentrated to 15.6 mg/mL using an Amicon Ultra-15 Centrifugal Filter Unit (Merck Millipore, Darmstadt, Germany). The human PPAR&#x003b3; R288A mutant LBD was expressed and purified in the same manner as the WT protein.</p></sec><sec id="sec4dot3-molecules-24-03562"><title>4.3. Crystallization</title><p>The purified PPAR&#x003b3; R288A mutant LBD and the coactivator SRC-1 peptide containing the LxxLL motif were mixed in a molar ratio of 1:2, in the presence or absence of a 7-fold molar excess of the PPAR&#x003b3; phosphorylation site inhibitor imatinib. After 24 h, the protein complexes were crystallized at 23 &#x000b0;C using the sitting-drop vapor diffusion method by mixing 0.2 &#x003bc;L of the purified protein solution and 0.2 &#x003bc;L of the reservoir solution. Crystals of imatinib-bound PPAR&#x003b3; R288A mutant LBD and ligand-free PPAR&#x003b3; R288A mutant LBD were obtained with a reservoir solution of 2.2 M sodium malonate at pH 7.0.</p></sec><sec id="sec4dot4-molecules-24-03562"><title>4.4. X-ray Data Collection</title><p>X-ray diffraction data for imatinib-bound PPAR&#x003b3; R288A mutant LBD were collected at 100 K using a Dectris PILATUS 2M-F pixel detector (Dectris Ltd., Baden, Switzerland) at the NE3A experimental station of Photon Factory, Japan. The X-ray data from the crystal of ligand-free PPAR&#x003b3; R288A mutant LBD were collected at 100 K using a Quantum Q270 CCD detector system (Area Detector Systems Corporation, Poway, CA, USA) at the BL-7A experimental station of Pohang Light Source, Korea. Raw X-ray diffraction data were processed and scaled using the program suit <italic>HKL2000</italic> [<xref rid="B36-molecules-24-03562" ref-type="bibr">36</xref>]. Crystals of imatinib-bound PPAR&#x003b3; R288A mutant LBD belonged to the space group <italic>P2<sub>1</sub>2<sub>1</sub>2</italic>, with unit cell parameters of a = 130.9 &#x000c5;, b = 52.8 &#x000c5;, c = 53.4 &#x000c5;. One monomer was present in the asymmetric unit, generating a Matthew&#x02019;s parameter and solvent fraction of 2.70 &#x000c5;<sup>3</sup>/Da and 54.5%, respectively. Crystals of ligand-free PPAR&#x003b3; R288A mutant LBD belonged to the space group <italic>P2<sub>1</sub>2<sub>1</sub>2</italic>, with unit cell parameters of a = 131.5 &#x000c5;, b = 52.7 &#x000c5;, c = 53.7 &#x000c5;. One monomer was present in the asymmetric unit, generating a Matthew&#x02019;s parameter and solvent fraction of 2.72 &#x000c5;<sup>3</sup>/Da and 54.9%, respectively. Data collection statistics are summarized in <xref rid="molecules-24-03562-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec4dot5-molecules-24-03562"><title>4.5. Structure Determination and Refinement</title><p>Both structures of imatinib-bound and ligand-free PPAR&#x003b3; R288A mutant LBD were solved by the molecular replacement method using the program <italic>MolRep</italic> with the ligand-free PPAR&#x003b3; WT LBD structure (PDB ID: 6JQ7) as a search model [<xref rid="B35-molecules-24-03562" ref-type="bibr">35</xref>,<xref rid="B37-molecules-24-03562" ref-type="bibr">37</xref>]. Subsequent model building was performed manually using the program <italic>COOT</italic> [<xref rid="B38-molecules-24-03562" ref-type="bibr">38</xref>]. Following this, the model was further refined using the program <italic>REFMAC5</italic>, including the bulk solvent correction [<xref rid="B39-molecules-24-03562" ref-type="bibr">39</xref>]. A total of 5% of the data were randomly excluded for the calculation of <italic>R<sub>free</sub></italic> [<xref rid="B40-molecules-24-03562" ref-type="bibr">40</xref>]. The reliability of the refined models was assessed using <italic>MolProbity</italic> [<xref rid="B41-molecules-24-03562" ref-type="bibr">41</xref>]. Refinement statistics are summarized in <xref rid="molecules-24-03562-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec4dot6-molecules-24-03562"><title>4.6. Surface Plasmon Resonance</title><p>The binding affinities of PPAR&#x003b3; WT LBD and R288A mutant LBD with imatinib were investigated by SPR kinetics experiments. All SPR measurements were performed at 25 &#x000b0;C using the Biacore T200 apparatus (GE Healthcare, Chicago, IL, USA). For immobilization, the amine coupling kit containing 0.1 M N-hydroxysuccinimide and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride on a CM5 sensor chip with HBS-EP buffer (10 mM HEPES at pH 7.5, 150 mM NaCl, 3 mM EDTA, and 0.005% p20) was used according to the manufacturer&#x02019;s protocol. Subsequently, 30 &#x003bc;g/mL of PPAR&#x003b3; WT LBD or R288A mutant LBD dissolved in 10 mM sodium acetate at pH 5.0 was injected at regular intervals until the immobilization level reached approximately 7000 response units (RU). The remaining activated carboxyl groups on the CM5 sensor chip surface were deactivated with 1 M ethanolamine at pH 8.5 for 400 s. The control experiment was treated identically with a reference flow cell without protein, and the response by the control was subtracted from each sample dataset. Imatinib at concentrations of 0.625, 1.25, 2.50, 5.00, and 10.0 &#x003bc;M in PBS buffer was injected over the PPAR&#x003b3; WT LBD chip or R288A mutant LBD chip at a rate of 30 &#x003bc;L/min for 120 s, followed by dissociation for 300 s in multi-cycle reactions. For rosiglitazone, experiments were conducted at lower concentrations than imatinib. The sensor chip surface was regenerated for 5 s with 5 mM NaOH between cycles. The SPR response data were fit to the simple bimolecular 1:1 Langmuir isotherm binding model to determine the equilibrium dissociation constant (<italic>Kd</italic>) using Biacore T200 evaluation software 3.0 (GE Healthcare, Chicago, IL, USA).</p></sec><sec id="sec4dot7-molecules-24-03562"><title>4.7. Accession Codes</title><p>Atomic coordinates and structure factors for ligand-free and imatinib-bound PPAR&#x003b3; R288A mutant LBD structures have been deposited in Protein Data Bank under the accession codes 6KTM and 6KTN, respectively.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank beamline staff for assistance during X-ray diffraction experiments at Pohang Light Source (beamlines BL-5C, BL-7A, and BL-11C) and Photon Factory (beamlines BL-1A, BL-5A, BL-17A, NE3A, and NW12A).</p></ack><fn-group><fn><p><bold>Sample Availability:</bold> Samples of the compounds are not available from the authors.</p></fn></fn-group><app-group><app id="app1-molecules-24-03562"><title>Supplementary Materials</title><p>The following are available online. Figure S1: Superposition of imatinib-bound ABL kinase domain (PDB ID: 1IEP) and imatinib-bound Syk kinase domain (PDB ID: 1XBB), Figure S2: Ribbon diagram of the H9&#x02013;H10 loop region in the ligand-free PPAR&#x003b3; WT LBD structure (PDB ID: 6JQ7), Figure S3: The hydrophobic interaction network in Arm3 region of PPAR&#x003b3; WT LBD, Figure S4: SPR analysis of the binding affinity for rosiglitazone of PPAR&#x003b3; WT LBD, Figure S5: Modeling of the ligand-free PPAR&#x003b3; WT LBD structure into the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure.</p><supplementary-material content-type="local-data" id="molecules-24-03562-s001"><media xlink:href="molecules-24-03562-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.Y.J. and B.W.H.; software, J.Y.J.; validation, J.Y.J., H.-J.K., and B.W.H.; investigation, J.Y.J., H.-J.K., and B.W.H.; data curation, J.Y.J.; writing&#x02014;original draft preparation, J.Y.J.; writing&#x02014;review and editing, J.Y.J., H.-J.K., and B.W.H.; visualization, J.Y.J.; supervision, B.W.H.; project administration, B.W.H.; funding acquisition, B.W.H.</p></notes><notes><title>Funding</title><p>This research was supported by the Tumor Microenvironment Global Core Research Center (grant no. 2011-0030001) and the Basic Science Research Programs (grant no. NRF-2019R1A2C1090251) funded by the National Research Foundation of the Ministry of Science and ICT of Korea. This work was also supported by the Brain Korea (BK21) PLUS program to the College of Pharmacy at the Seoul National University.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-24-03562"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallastegui</surname><given-names>N.</given-names></name><name><surname>Mackinnon</surname><given-names>J.A.G.</given-names></name><name><surname>Fletterick</surname><given-names>R.J.</given-names></name><name><surname>Estebanez-Perpina</surname><given-names>E.</given-names></name></person-group><article-title>Advances in our structural understanding of orphan nuclear receptors</article-title><source>Trends Biochem. Sci.</source><year>2015</year><volume>40</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.11.002</pub-id><?supplied-pmid 25499868?><pub-id pub-id-type="pmid">25499868</pub-id></element-citation></ref><ref id="B2-molecules-24-03562"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>J.</given-names></name><name><surname>Moller</surname><given-names>D.E.</given-names></name></person-group><article-title>The mechanisms of action of PPARs</article-title><source>Annu. Rev. Med.</source><year>2002</year><volume>53</volume><fpage>409</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.53.082901.104018</pub-id><?supplied-pmid 11818483?><pub-id pub-id-type="pmid">11818483</pub-id></element-citation></ref><ref id="B3-molecules-24-03562"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Auboeuf</surname><given-names>D.</given-names></name><name><surname>Raspe</surname><given-names>E.</given-names></name><name><surname>Schoonjans</surname><given-names>K.</given-names></name><name><surname>Lefebvre</surname><given-names>A.M.</given-names></name><name><surname>Saladin</surname><given-names>R.</given-names></name><name><surname>Najib</surname><given-names>J.</given-names></name><name><surname>Laville</surname><given-names>M.</given-names></name><name><surname>Fruchart</surname><given-names>J.C.</given-names></name><name><surname>Deeb</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The organization, promoter analysis, and expression of the human PPAR gamma gene</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>18779</fpage><lpage>18789</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.30.18779</pub-id><?supplied-pmid 9228052?><pub-id pub-id-type="pmid">9228052</pub-id></element-citation></ref><ref id="B4-molecules-24-03562"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Welch</surname><given-names>J.</given-names></name><name><surname>Najib</surname><given-names>J.</given-names></name><name><surname>Witztum</surname><given-names>J.L.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name><name><surname>Palinski</surname><given-names>W.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><article-title>Expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>7614</fpage><lpage>7619</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7614</pub-id><?supplied-pmid 9636198?><pub-id pub-id-type="pmid">9636198</pub-id></element-citation></ref><ref id="B5-molecules-24-03562"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group><article-title>The many faces of PPAR gamma</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.11.026</pub-id><?supplied-pmid 16360030?><pub-id pub-id-type="pmid">16360030</pub-id></element-citation></ref><ref id="B6-molecules-24-03562"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>R.T.</given-names></name><name><surname>Wisely</surname><given-names>G.B.</given-names></name><name><surname>Westin</surname><given-names>S.</given-names></name><name><surname>Cobb</surname><given-names>J.E.</given-names></name><name><surname>Lambert</surname><given-names>M.H.</given-names></name><name><surname>Kurokawa</surname><given-names>R.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.G.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name><name><surname>Milburn</surname><given-names>M.V.</given-names></name></person-group><article-title>Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma</article-title><source>Nature</source><year>1998</year><volume>395</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/25931</pub-id><?supplied-pmid 9744270?><pub-id pub-id-type="pmid">9744270</pub-id></element-citation></ref><ref id="B7-molecules-24-03562"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>T.</given-names></name><name><surname>Fairall</surname><given-names>L.</given-names></name><name><surname>Amin</surname><given-names>K.</given-names></name><name><surname>Inaba</surname><given-names>Y.</given-names></name><name><surname>Szanto</surname><given-names>A.</given-names></name><name><surname>Balint</surname><given-names>B.L.</given-names></name><name><surname>Nagy</surname><given-names>L.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Schwabe</surname><given-names>J.W.R.</given-names></name></person-group><article-title>Structural basis for the activation of PPAR gamma by oxidized fatty acids</article-title><source>Nat. Struct. Mol. Biol.</source><year>2008</year><volume>15</volume><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1474</pub-id><pub-id pub-id-type="pmid">19172745</pub-id></element-citation></ref><ref id="B8-molecules-24-03562"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>J.Y.</given-names></name><name><surname>Bae</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Il Choi</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Park</surname><given-names>S.B.</given-names></name><name><surname>Suh</surname><given-names>S.W.</given-names></name><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Han</surname><given-names>B.W.</given-names></name></person-group><article-title>Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPAR gamma</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-18274-1</pub-id><pub-id pub-id-type="pmid">29311579</pub-id></element-citation></ref><ref id="B9-molecules-24-03562"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>J.P.</given-names></name><name><surname>Akiyama</surname><given-names>T.E.</given-names></name><name><surname>Meinke</surname><given-names>P.T.</given-names></name></person-group><article-title>PPARs: Therapeutic targets for metabolic disease</article-title><source>Trends Pharmacol. Sci.</source><year>2005</year><volume>26</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2005.03.003</pub-id><pub-id pub-id-type="pmid">15860371</pub-id></element-citation></ref><ref id="B10-molecules-24-03562"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>S.E.</given-names></name><name><surname>Wolski</surname><given-names>K.</given-names></name></person-group><article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>2457</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa072761</pub-id><pub-id pub-id-type="pmid">17517853</pub-id></element-citation></ref><ref id="B11-molecules-24-03562"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruning</surname><given-names>J.B.</given-names></name><name><surname>Chalmers</surname><given-names>M.J.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Busby</surname><given-names>S.A.</given-names></name><name><surname>Karnenecka</surname><given-names>T.M.</given-names></name><name><surname>He</surname><given-names>Y.J.</given-names></name><name><surname>Nettles</surname><given-names>K.W.</given-names></name><name><surname>Griffin</surname><given-names>P.R.</given-names></name></person-group><article-title>Partial agonists activate PPAR gamma using a helix 12 independent mechanism</article-title><source>Structure</source><year>2007</year><volume>15</volume><fpage>1258</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.str.2007.07.014</pub-id><?supplied-pmid 17937915?><pub-id pub-id-type="pmid">17937915</pub-id></element-citation></ref><ref id="B12-molecules-24-03562"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>T.S.</given-names></name><name><surname>Chalmers</surname><given-names>M.J.</given-names></name><name><surname>Novick</surname><given-names>S.</given-names></name><name><surname>Kuruvilla</surname><given-names>D.S.</given-names></name><name><surname>Chang</surname><given-names>M.R.</given-names></name><name><surname>Kamenecka</surname><given-names>T.M.</given-names></name><name><surname>Rance</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>B.A.</given-names></name><name><surname>Burris</surname><given-names>T.P.</given-names></name><name><surname>Griffin</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>Ligand and receptor dynamics contribute to the mechanism of graded PPARgamma agonism</article-title><source>Structure</source><year>2012</year><volume>20</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.10.018</pub-id><?supplied-pmid 22244763?><pub-id pub-id-type="pmid">22244763</pub-id></element-citation></ref><ref id="B13-molecules-24-03562"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>L.P.</given-names></name><name><surname>El-Houri</surname><given-names>R.B.</given-names></name></person-group><article-title>Development of an In Vitro Screening Platform for the Identification of Partial PPAR gamma Agonists as a Source for Antidiabetic Lead Compounds</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2431</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23102431</pub-id><?supplied-pmid 30248999?><pub-id pub-id-type="pmid">30248999</pub-id></element-citation></ref><ref id="B14-molecules-24-03562"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.H.</given-names></name><name><surname>Banks</surname><given-names>A.S.</given-names></name><name><surname>Estall</surname><given-names>J.L.</given-names></name><name><surname>Kajimura</surname><given-names>S.</given-names></name><name><surname>Bostrom</surname><given-names>P.</given-names></name><name><surname>Laznik</surname><given-names>D.</given-names></name><name><surname>Ruas</surname><given-names>J.L.</given-names></name><name><surname>Chalmers</surname><given-names>M.J.</given-names></name><name><surname>Kamenecka</surname><given-names>T.M.</given-names></name><name><surname>Bluher</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR gamma by Cdk5</article-title><source>Nature</source><year>2010</year><volume>466</volume><fpage>451</fpage><pub-id pub-id-type="doi">10.1038/nature09291</pub-id><?supplied-pmid 20651683?><pub-id pub-id-type="pmid">20651683</pub-id></element-citation></ref><ref id="B15-molecules-24-03562"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>T.S.</given-names></name><name><surname>Giri</surname><given-names>P.K.</given-names></name><name><surname>de Vera</surname><given-names>I.M.S.</given-names></name><name><surname>Marciano</surname><given-names>D.P.</given-names></name><name><surname>Kuruvilla</surname><given-names>D.S.</given-names></name><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>Blayo</surname><given-names>A.L.</given-names></name><name><surname>Kamenecka</surname><given-names>T.M.</given-names></name><name><surname>Burris</surname><given-names>T.P.</given-names></name><name><surname>Griffin</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>An alternate binding site for PPAR gamma ligands</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3571</fpage><pub-id pub-id-type="doi">10.1038/ncomms4571</pub-id><?supplied-pmid 24705063?><pub-id pub-id-type="pmid">24705063</pub-id></element-citation></ref><ref id="B16-molecules-24-03562"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>H.</given-names></name><name><surname>Jang</surname><given-names>J.Y.</given-names></name><name><surname>Choi</surname><given-names>S.S.</given-names></name><name><surname>Lee</surname><given-names>J.J.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Jo</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>K.J.</given-names></name><name><surname>Choi</surname><given-names>J.H.</given-names></name><name><surname>Suh</surname><given-names>S.W.</given-names></name><name><surname>Park</surname><given-names>S.B.</given-names></name></person-group><article-title>Mechanistic elucidation guided by covalent inhibitors for the development of anti-diabetic PPAR gamma ligands</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>5523</fpage><lpage>5529</lpage><pub-id pub-id-type="doi">10.1039/C6SC01279E</pub-id><pub-id pub-id-type="pmid">30034693</pub-id></element-citation></ref><ref id="B17-molecules-24-03562"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>B.J.</given-names></name><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Buchdunger</surname><given-names>E.</given-names></name><name><surname>Ohno</surname><given-names>S.</given-names></name><name><surname>Segal</surname><given-names>G.M.</given-names></name><name><surname>Fanning</surname><given-names>S.</given-names></name><name><surname>Zimmermann</surname><given-names>J.</given-names></name><name><surname>Lydon</surname><given-names>N.B.</given-names></name></person-group><article-title>Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</article-title><source>Nat. Med.</source><year>1996</year><volume>2</volume><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/nm0596-561</pub-id><pub-id pub-id-type="pmid">8616716</pub-id></element-citation></ref><ref id="B18-molecules-24-03562"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duensing</surname><given-names>A.</given-names></name><name><surname>Medeiros</surname><given-names>F.</given-names></name><name><surname>McConarty</surname><given-names>B.</given-names></name><name><surname>Joseph</surname><given-names>N.E.</given-names></name><name><surname>Panigrahy</surname><given-names>D.</given-names></name><name><surname>Singer</surname><given-names>S.</given-names></name><name><surname>Fletcher</surname><given-names>C.D.M.</given-names></name><name><surname>Demetri</surname><given-names>G.D.</given-names></name><name><surname>Fletcher</surname><given-names>J.A.</given-names></name></person-group><article-title>Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>3999</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207525</pub-id><pub-id pub-id-type="pmid">15007386</pub-id></element-citation></ref><ref id="B19-molecules-24-03562"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardanani</surname><given-names>A.</given-names></name><name><surname>Reeder</surname><given-names>T.</given-names></name><name><surname>Porrata</surname><given-names>L.F.</given-names></name><name><surname>Li</surname><given-names>C.Y.</given-names></name><name><surname>Tazelaar</surname><given-names>H.D.</given-names></name><name><surname>Baxter</surname><given-names>E.J.</given-names></name><name><surname>Witzig</surname><given-names>T.E.</given-names></name><name><surname>Cross</surname><given-names>N.C.P.</given-names></name><name><surname>Tefferi</surname><given-names>A.</given-names></name></person-group><article-title>Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>3391</fpage><lpage>3397</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-10-3103</pub-id><pub-id pub-id-type="pmid">12506022</pub-id></element-citation></ref><ref id="B20-molecules-24-03562"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>B.J.</given-names></name><name><surname>Lydon</surname><given-names>N.B.</given-names></name></person-group><article-title>Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia</article-title><source>J. Clin. Investig.</source><year>2000</year><volume>105</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1172/JCI9083</pub-id><pub-id pub-id-type="pmid">10619854</pub-id></element-citation></ref><ref id="B21-molecules-24-03562"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S.S.</given-names></name><name><surname>Kim</surname><given-names>E.S.</given-names></name><name><surname>Jung</surname><given-names>J.E.</given-names></name><name><surname>Marciano</surname><given-names>D.P.</given-names></name><name><surname>Jo</surname><given-names>A.</given-names></name><name><surname>Koo</surname><given-names>J.Y.</given-names></name><name><surname>Choi</surname><given-names>S.Y.</given-names></name><name><surname>Yang</surname><given-names>Y.R.</given-names></name><name><surname>Jang</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>E.K.</given-names></name><etal/></person-group><article-title>PPAR gamma Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue</article-title><source>Diabetes</source><year>2016</year><volume>65</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.2337/db15-1382</pub-id><?supplied-pmid 26740599?><pub-id pub-id-type="pmid">26740599</pub-id></element-citation></ref><ref id="B22-molecules-24-03562"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>W.M.</given-names></name><name><surname>Wright</surname><given-names>H.M.</given-names></name><name><surname>Kum</surname><given-names>J.B.</given-names></name><name><surname>Aaltonen</surname><given-names>L.A.</given-names></name><name><surname>de la Chapelle</surname><given-names>A.</given-names></name><name><surname>Spiegelman</surname><given-names>B.M.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name></person-group><article-title>Loss-of-function mutations in PPAR gamma associated with human colon cancer</article-title><source>Mol. Cell</source><year>1999</year><volume>3</volume><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(01)80012-5</pub-id><pub-id pub-id-type="pmid">10394368</pub-id></element-citation></ref><ref id="B23-molecules-24-03562"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>R.A.</given-names></name><name><surname>Swindells</surname><given-names>M.B.</given-names></name></person-group><article-title>LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery</article-title><source>J. Chem. Inf. Model.</source><year>2011</year><volume>51</volume><fpage>2778</fpage><lpage>2786</lpage><pub-id pub-id-type="doi">10.1021/ci200227u</pub-id><?supplied-pmid 21919503?><pub-id pub-id-type="pmid">21919503</pub-id></element-citation></ref><ref id="B24-molecules-24-03562"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagar</surname><given-names>B.</given-names></name><name><surname>Bornmann</surname><given-names>W.G.</given-names></name><name><surname>Pellicena</surname><given-names>P.</given-names></name><name><surname>Schindler</surname><given-names>T.</given-names></name><name><surname>Veach</surname><given-names>D.R.</given-names></name><name><surname>Miller</surname><given-names>W.T.</given-names></name><name><surname>Clarkson</surname><given-names>B.</given-names></name><name><surname>Kuriyan</surname><given-names>J.</given-names></name></person-group><article-title>Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>4236</fpage><lpage>4243</lpage><?supplied-pmid 12154025?><pub-id pub-id-type="pmid">12154025</pub-id></element-citation></ref><ref id="B25-molecules-24-03562"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwell</surname><given-names>S.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Badger</surname><given-names>J.</given-names></name><name><surname>Buchanan</surname><given-names>M.D.</given-names></name><name><surname>Feil</surname><given-names>I.K.</given-names></name><name><surname>Froning</surname><given-names>K.J.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Hendle</surname><given-names>J.</given-names></name><name><surname>Keegan</surname><given-names>K.</given-names></name><name><surname>Leon</surname><given-names>B.C.</given-names></name><etal/></person-group><article-title>A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>55827</fpage><lpage>55832</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409792200</pub-id><?supplied-pmid 15507431?><pub-id pub-id-type="pmid">15507431</pub-id></element-citation></ref><ref id="B26-molecules-24-03562"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carugo</surname><given-names>O.</given-names></name><name><surname>Argos</surname><given-names>P.</given-names></name></person-group><article-title>Accessibility to internal cavities and ligand binding sites monitored by protein crystallographic thermal factors</article-title><source>Proteins</source><year>1998</year><volume>31</volume><fpage>201</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(19980501)31:2&#x0003c;201::AID-PROT9&#x0003e;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">9593193</pub-id></element-citation></ref><ref id="B27-molecules-24-03562"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>J.M.</given-names></name><name><surname>Moore</surname><given-names>L.B.</given-names></name><name><surname>Smitholiver</surname><given-names>T.A.</given-names></name><name><surname>Wilkison</surname><given-names>W.O.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Kliewer</surname><given-names>S.A.</given-names></name></person-group><article-title>An Antidiabetic Thiazolidinedione Is a High-Affinity Ligand for Peroxisome Proliferator-Activated Receptor Gamma(Ppar-Gamma)</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>12953</fpage><lpage>12956</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.22.12953</pub-id><pub-id pub-id-type="pmid">7768881</pub-id></element-citation></ref><ref id="B28-molecules-24-03562"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.H.</given-names></name><name><surname>Banks</surname><given-names>A.S.</given-names></name><name><surname>Kamenecka</surname><given-names>T.M.</given-names></name><name><surname>Busby</surname><given-names>S.A.</given-names></name><name><surname>Chalmers</surname><given-names>M.J.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Kuruvilla</surname><given-names>D.S.</given-names></name><name><surname>Shin</surname><given-names>Y.S.</given-names></name><name><surname>He</surname><given-names>Y.J.</given-names></name><name><surname>Bruning</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Antidiabetic actions of a non-agonist PPAR gamma ligand blocking Cdk5-mediated phosphorylation</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>477</fpage><pub-id pub-id-type="doi">10.1038/nature10383</pub-id><pub-id pub-id-type="pmid">21892191</pub-id></element-citation></ref><ref id="B29-molecules-24-03562"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>J.Y.</given-names></name><name><surname>Koh</surname><given-names>M.</given-names></name><name><surname>Bae</surname><given-names>H.</given-names></name><name><surname>An</surname><given-names>D.R.</given-names></name><name><surname>Im</surname><given-names>H.N.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Yoon</surname><given-names>J.Y.</given-names></name><name><surname>Yoon</surname><given-names>H.J.</given-names></name><name><surname>Han</surname><given-names>B.W.</given-names></name><name><surname>Park</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Structural basis for differential activities of enantiomeric PPAR gamma agonists: Binding of S35 to the alternate site</article-title><source>Biochim. Biophys. Acta (BBA) Proteins Proteom.</source><year>2017</year><volume>1865</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2017.03.008</pub-id></element-citation></ref><ref id="B30-molecules-24-03562"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburn</surname><given-names>T.T.</given-names></name><name><surname>Thor</surname><given-names>K.B.</given-names></name></person-group><article-title>Drug repositioning: Identifying and developing new uses for existing drugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2004</year><volume>3</volume><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1038/nrd1468</pub-id><pub-id pub-id-type="pmid">15286734</pub-id></element-citation></ref><ref id="B31-molecules-24-03562"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro Filho</surname><given-names>H.V.</given-names></name><name><surname>Guerra</surname><given-names>J.V.</given-names></name><name><surname>Cagliari</surname><given-names>R.</given-names></name><name><surname>Batista</surname><given-names>F.A.H.</given-names></name><name><surname>Le Maire</surname><given-names>A.</given-names></name><name><surname>Oliveira</surname><given-names>P.S.L.</given-names></name><name><surname>Figueira</surname><given-names>A.C.M.</given-names></name></person-group><article-title>Exploring the mechanism of PPAR&#x003b3; phosphorylation mediated by CDK5</article-title><source>J. Struct. Biol.</source><year>2019</year><volume>207</volume><fpage>317</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2019.07.007</pub-id><?supplied-pmid 31319193?><pub-id pub-id-type="pmid">31319193</pub-id></element-citation></ref><ref id="B32-molecules-24-03562"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostberg</surname><given-names>T.</given-names></name><name><surname>Svensson</surname><given-names>S.</given-names></name><name><surname>Selen</surname><given-names>G.</given-names></name><name><surname>Uppenberg</surname><given-names>J.</given-names></name><name><surname>Thor</surname><given-names>M.</given-names></name><name><surname>Sundbom</surname><given-names>M.</given-names></name><name><surname>Sydow-Backman</surname><given-names>M.</given-names></name><name><surname>Gustavsson</surname><given-names>A.L.</given-names></name><name><surname>Jendeberg</surname><given-names>L.</given-names></name></person-group><article-title>A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>41124</fpage><lpage>41130</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401552200</pub-id><?supplied-pmid 15258145?><pub-id pub-id-type="pmid">15258145</pub-id></element-citation></ref><ref id="B33-molecules-24-03562"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>C.</given-names></name><name><surname>de Groot</surname><given-names>J.C.</given-names></name><name><surname>Prasad</surname><given-names>A.</given-names></name><name><surname>Freiwald</surname><given-names>A.</given-names></name><name><surname>Quedenau</surname><given-names>C.</given-names></name><name><surname>Kliem</surname><given-names>M.</given-names></name><name><surname>Witzke</surname><given-names>A.</given-names></name><name><surname>Kodelja</surname><given-names>V.</given-names></name><name><surname>Han</surname><given-names>C.T.</given-names></name><name><surname>Giegold</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Amorfrutins are potent antidiabetic dietary natural products</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>7257</fpage><lpage>7262</lpage><pub-id pub-id-type="doi">10.1073/pnas.1116971109</pub-id><?supplied-pmid 22509006?><pub-id pub-id-type="pmid">22509006</pub-id></element-citation></ref><ref id="B34-molecules-24-03562"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>V.</given-names></name><name><surname>Huang</surname><given-names>P.X.</given-names></name><name><surname>Hamuro</surname><given-names>Y.</given-names></name><name><surname>Raghuram</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.J.</given-names></name><name><surname>Burris</surname><given-names>T.P.</given-names></name><name><surname>Rastinejad</surname><given-names>F.</given-names></name></person-group><article-title>Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA</article-title><source>Nature</source><year>2008</year><volume>456</volume><fpage>350</fpage><pub-id pub-id-type="doi">10.1038/nature07413</pub-id><?supplied-pmid 19043829?><pub-id pub-id-type="pmid">19043829</pub-id></element-citation></ref><ref id="B35-molecules-24-03562"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Suh</surname><given-names>S.W.</given-names></name><name><surname>Park</surname><given-names>S.B.</given-names></name><name><surname>Han</surname><given-names>B.W.</given-names></name></person-group><article-title>Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPAR gamma phosphorylation</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>11168</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-47672-w</pub-id><pub-id pub-id-type="pmid">31371757</pub-id></element-citation></ref><ref id="B36-molecules-24-03562"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otwinowski</surname><given-names>Z.</given-names></name><name><surname>Minor</surname><given-names>W.</given-names></name></person-group><article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title><source>Method Enzymol.</source><year>1997</year><volume>276</volume><fpage>307</fpage><lpage>326</lpage></element-citation></ref><ref id="B37-molecules-24-03562"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vagin</surname><given-names>A.</given-names></name><name><surname>Teplyakov</surname><given-names>A.</given-names></name></person-group><article-title>Molecular replacement with MOLREP</article-title><source>Acta Crystallogr. D</source><year>2010</year><volume>66</volume><fpage>22</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042589</pub-id><pub-id pub-id-type="pmid">20057045</pub-id></element-citation></ref><ref id="B38-molecules-24-03562"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Lohkamp</surname><given-names>B.</given-names></name><name><surname>Scott</surname><given-names>W.G.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr. D</source><year>2010</year><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="B39-molecules-24-03562"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>G.N.</given-names></name><name><surname>Vagin</surname><given-names>A.A.</given-names></name><name><surname>Dodson</surname><given-names>E.J.</given-names></name></person-group><article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title><source>Acta Crystallogr. Sect. D Struct. Biol.</source><year>1997</year><volume>53</volume><fpage>240</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1107/S0907444996012255</pub-id></element-citation></ref><ref id="B40-molecules-24-03562"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunger</surname><given-names>A.T.</given-names></name></person-group><article-title>Free R-Value&#x02014;A Novel Statistical Quantity for Assessing the Accuracy of Crystal-Structures</article-title><source>Nature</source><year>1992</year><volume>355</volume><fpage>472</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/355472a0</pub-id><pub-id pub-id-type="pmid">18481394</pub-id></element-citation></ref><ref id="B41-molecules-24-03562"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Arendall</surname><given-names>W.B.</given-names></name><name><surname>Headd</surname><given-names>J.J.</given-names></name><name><surname>Keedy</surname><given-names>D.A.</given-names></name><name><surname>Immormino</surname><given-names>R.M.</given-names></name><name><surname>Kapral</surname><given-names>G.J.</given-names></name><name><surname>Murray</surname><given-names>L.W.</given-names></name><name><surname>Richardson</surname><given-names>J.S.</given-names></name><name><surname>Richardson</surname><given-names>D.C.</given-names></name></person-group><article-title>MolProbity: All-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallogr. Sect. D Struct. Biol.</source><year>2010</year><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id><?supplied-pmid 20057044?><pub-id pub-id-type="pmid">20057044</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-24-03562-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structures of imatinib and rosiglitazone.</p></caption><graphic xlink:href="molecules-24-03562-g001"/></fig><fig id="molecules-24-03562-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Overall structure of imatinib-bound PPAR&#x003b3; R288A mutant LBD. (<bold>A</bold>) Ribbon diagram of imatinib-bound PPAR&#x003b3; R288A mutant LBD (light teal) with the helical LxxLL motif-containing peptide (grey). Imatinib molecule and the Cdk5-mediated phosphorylation site Ser245 are shown in yellow orange and light teal stick models, respectively. The electron density for imatinib in the <italic>mFo&#x02013;DFc</italic> omit map is displayed as a wheat teal-colored mesh (contoured at 2.5&#x003c3;). (<bold>B</bold>) Schematic diagram of the interactions between PPAR&#x003b3; R288A mutant LBD and imatinib, as calculated using LigPlot+ [<xref rid="B23-molecules-24-03562" ref-type="bibr">23</xref>]. Hydrophobic effects are indicated by atoms with spokes and spoked arcs. Carbon, nitrogen, and oxygen atoms are colored in black, blue, and red, respectively. (<bold>C</bold>) A magnified image of bound imatinib in a stick model with the <italic>mFo&#x02013;DFc</italic> omit electron density map (contoured at 2.5&#x003c3;).</p></caption><graphic xlink:href="molecules-24-03562-g002"/></fig><fig id="molecules-24-03562-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Superposition of imatinib and other reported ligands from known PPAR&#x003b3; complex structures. In total, 144 ligand-bound PPAR&#x003b3; LBD structures in the protein data bank (PDB) were superimposed onto the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure (ribbon in light teal). Yellow orange stick model indicates imatinib and salmon lines represent the other ligands. Tyr473 of helix H12 and the Cdk5-mediated phosphorylation site Ser245 are shown in light teal stick models. Right panel shows a close-up view of PPAR&#x003b3; LBP, with the Arm1, Arm2, and Arm3 regions of PPAR&#x003b3; LBP labeled.</p></caption><graphic xlink:href="molecules-24-03562-g003"/></fig><fig id="molecules-24-03562-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Comparison of imatinib-bound PPAR&#x003b3; R288A mutant LBD, ligand-free PPAR&#x003b3; R288A mutant LBD, and ligand-free PPAR&#x003b3; wild-type (WT) LBD structures with respect to C&#x003b1; RMSD and normalized B-factors. (<bold>A</bold>) Comparison of the C&#x003b1; root-mean-square deviation (RMSD) values for the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure against the ligand-free PPAR&#x003b3; R288A mutant LBD and ligand-free PPAR&#x003b3; WT LBD (PDB ID: 6JQ7) structures. Red and blue lines represent the RMSD values for imatinib-bound PPAR&#x003b3; R288A mutant LBD vs. ligand-free PPAR&#x003b3; R288A mutant LBD and imatinib-bound PPAR&#x003b3; R288A mutant LBD vs. ligand-free PPAR&#x003b3; WT LBD structures, respectively. Grey lines represent the C&#x003b1; RMSD values for ligand-free PPAR&#x003b3; R288A mutant LBD vs. ligand-free PPAR&#x003b3; WT LBD structures. Secondary structural elements are represented along the residue numbers. The H9&#x02013;H10 loop region between residues Asn424 and Leu431 exhibiting a large conformational change is marked by a black-dashed box. (<bold>B</bold>) Comparison of the normalized B-factors for imatinib-bound PPAR&#x003b3; R288A mutant LBD, ligand-free PPAR&#x003b3; R288A mutant LBD, and ligand-free PPAR&#x003b3; WT LBD structures. The normalized B-factors for imatinib-bound PPAR&#x003b3; R288A mutant LBD, ligand-free PPAR&#x003b3; R288A mutant LBD, and ligand-free PPAR&#x003b3; WT LBD structures are represented in red, blue, and grey lines, respectively. Helix H2&#x02032; and the &#x003a9; loop, which exhibited enhanced thermal stabilities in the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure, is marked by a black-dashed box.</p></caption><graphic xlink:href="molecules-24-03562-g004"/></fig><fig id="molecules-24-03562-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Side views of imatinib-bound and ligand-free PPAR&#x003b3; R288A mutant LBD structures. (<bold>A</bold>) Superposition of ligand-free (light orange) and imatinib-bound (light teal) PPAR&#x003b3; R288A mutant LBD structures. The region with a large conformational change is represented by a cyan-dashed box. (<bold>B</bold>) A magnified ribbon diagram of the H9&#x02013;H10 loop region in the ligand-free PPAR&#x003b3; R288A mutant LBD structure. The residues Asp380, Ser382, and Asn424 are shown in stick models with <italic>2mFo&#x02013;DFc</italic> electron density maps (in grey; contoured at 1.0&#x003c3;). Dashed lines represent the distance between residues, and the corresponding distances (&#x000c5;) are labeled. (<bold>C</bold>) A magnified ribbon diagram of the H9&#x02013;H10 loop region in the imatinib-bound PPAR&#x003b3; R288A mutant LBD structure. The residues are represented in the same way as the ligand-free structure (A) with the violet-colored electron density maps.</p></caption><graphic xlink:href="molecules-24-03562-g005"/></fig><fig id="molecules-24-03562-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>The hydrophobic interaction network in Arm3 region of PPAR&#x003b3; LBD. (<bold>A</bold>) The ligand-free PPAR&#x003b3; R288A mutant LBD structure is shown in a ribbon diagram (light orange), and the residues forming the hydrophobic interaction network are represented by stick models. Dashed line represents the distance between Leu255 and Ile341, and the corresponding distances (&#x000c5;) are labeled. (<bold>B</bold>) The imatinib-bound PPAR&#x003b3; R288A mutant LBD structure is shown in a ribbon diagram (light teal). Imatinib is shown in a yellow orange stick model. All other marks are shown similarly to (A).</p></caption><graphic xlink:href="molecules-24-03562-g006"/></fig><fig id="molecules-24-03562-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Surface plasmon resonance (SPR) analyses of the binding affinities for imatinib of PPAR&#x003b3; WT LBD and PPAR&#x003b3; R288A mutant LBD. SPR sensorgrams for imatinib binding of PPAR&#x003b3; R288A mutant LBD (<bold>A</bold>) and PPAR&#x003b3; WT LBD (<bold>B</bold>) are shown. Sensorgrams show binding at increasing concentrations (0.625, 1.25, 2.50, 5.00, and 10.0 &#x000b5;M) of imatinib to immobilized PPAR&#x003b3; R288A mutant LBD and PPAR&#x003b3; WT LBD. The calculated <italic>Kd</italic> values are also shown.</p></caption><graphic xlink:href="molecules-24-03562-g007"/></fig><table-wrap id="molecules-24-03562-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-24-03562-t001_Table 1</object-id><label>Table 1</label><caption><p>Statistics for the data collection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Imatinib-Bound <break/>(PDB ID: 6KTN)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ligand-Free <break/>(PDB ID: 6KTM)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">X-ray source</td><td align="center" valign="middle" rowspan="1" colspan="1">PF-NE3A</td><td align="center" valign="middle" rowspan="1" colspan="1">PLS-7A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">X-ray wavelength (&#x000c5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97933</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Space group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P2<sub>1</sub>2<sub>1</sub>2</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P2<sub>1</sub>2<sub>1</sub>2</italic>
</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Unit cell parameters</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">a, b, c (&#x000c5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">130.93, 52.78, 53.44</td><td align="center" valign="middle" rowspan="1" colspan="1">131.47, 52.70, 53.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1; = &#x003b2; = &#x003b3; (&#x000b0;)</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Resolution range (&#x000c5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0&#x02013;2.75 (2.80&#x02013;2.75) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">50.0&#x02013;2.70 (2.75&#x02013;2.70) <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total/unique reflections</td><td align="center" valign="middle" rowspan="1" colspan="1">69,349/10,176</td><td align="center" valign="middle" rowspan="1" colspan="1">101,468/10,775</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Completeness (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">99.9 (99.6) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">99.6 (100.0) <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>&#x0003c;I/&#x003c3;I&#x0003e;</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">30.1 (2.7) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">41.1 (4.1) <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R<sub>merge</sub></italic><sup>b</sup> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.9 (67.9) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7.9 (70.4) <sup>a</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CC<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.971 (0.860) <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.975 (0.875) <sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Values in parentheses refer to the highest resolution shell. <sup>b</sup>
<italic>R<sub>merge</sub></italic> = &#x003a3;h&#x003a3;i|I(h)i&#x02013;&#x0003c;I(h)&#x0003e;|/&#x003a3;h&#x003a3;i I(h)i, where I(h) is the intensity of reflection h, &#x003a3;h is the sum over all reflections, and &#x003a3;i is the sum over i measurements of reflection h.</p></fn></table-wrap-foot></table-wrap><table-wrap id="molecules-24-03562-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-24-03562-t002_Table 2</object-id><label>Table 2</label><caption><p>Statistics for the model refinement.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Imatinib-Bound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ligand-Free</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Resolution range (&#x000c5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">30.0&#x02013;2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">30.0&#x02013;2.70</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub><sup>a</sup> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.1/25.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.7/25.8</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No. of nonhydrogen atoms</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Protein</td><td align="center" valign="middle" rowspan="1" colspan="1">2216</td><td align="center" valign="middle" rowspan="1" colspan="1">2174</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ligand</td><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water oxygen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Average <italic>B</italic> factor (&#x000c5;<sup>2</sup>)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Protein</td><td align="center" valign="middle" rowspan="1" colspan="1">48.3</td><td align="center" valign="middle" rowspan="1" colspan="1">77.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ligand</td><td align="center" valign="middle" rowspan="1" colspan="1">56.1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water oxygen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.4</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">R.m.s. deviations from ideal geometry</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bond lengths (&#x000c5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bond angles (&#x000b0;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Ramachandran plot <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Favored/Outliers (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">93.3/0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">98.5/0.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor rotamers <sup>b</sup> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup><italic>R</italic><sub>work</sub> = &#x003a3;||<italic>F</italic><sub>obs</sub>| &#x02013; |<italic>F</italic><sub>calc</sub>||/&#x003a3; |<italic>F</italic><sub>obs</sub>|, where <italic>R</italic><sub>free</sub> is calculated for a randomly chosen 5% of reflections, which were not used for structure refinement and <italic>R</italic><sub>work</sub> is calculated for the remaining reflections. <sup>b</sup> Values obtained using <italic>MolProbity</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>